2023年度発表論文等一覧

原著論文－英文

1. Kamegai K, Iwamoto N, Ishikane M, Yamamoto K, Horii K, Kubota S, Hangaishi A, Shimazu H, Togano T, Yamashita H, Yamada Y, Ohmagari N.
   A novel protocol for de-isolating moderately and severely immunocompromised COVID-19 patients.
   Glob Health Med 5(6):366-371, 2023.
2. Terada M, Saito S, Kutsuna S, Kinoshita-Iwamoto N, Togano T, Hangaishi A, Shiratori K, Takamatsu Y, Maeda K, Ishizaka Y, Ohtsu H, Satake M, Mitsuya H, Ohmagari N.
   Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals.
   Life (Basel) 13(11):2184, 2023.
3. Takamatsu H, Matsuda T, Mizuno S, Takahashi T, Fuchida SI, Hanamura I, Kataoka K, Tsukada N, Matsumoto M, Hangaishi A, Doki N, Uchida N, Sawa M, Maruyama Y, Kurahashi S, Nagafuji K, Harazaki Y, Kako S, Iida S, Ichinohe T, Kanda Y, Atsuta Y, Sunami K; Multiple Myeloma Working Group in the Japanese Society for Transplantation and Cellular Therapy.
   Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs.
   Haematologica 108(12):3399-3408, 2023.
4. Okada Y, Kimura F, Kurita N, Takahashi H, Shimazu Y, Mizuno S, Uchida N, Kataoka K, Hiramoto N, Ota S, Kako S, Tsukada N, Kanda Y, Kurahashi S, Doki N, Nishikawa A, Kim SW, Hangaishi A, Kanda J, Fukuda T, Atsuta Y, Kondo E, Kawamura K, Nakasone H.
   Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma.
   Cytotherapy 25(11):1212-1219, 2023.
5. Saito S, Kutsuna S, Akifumi I, Hase R, Oda R, Terada J, Shimizu Y, Uemura Y, Takamatsu Y, Yasuhara A, Shiratori K, Satake M, Sakamoto N, Miyazaki Y, Shimizu H, Togano T, Matsunaga A, Okuma K, Hamaguchi I, Fujisawa K, Nagashima M, Ashida S, Terada M, Kimura A, Morioka S, Matsubayashi K, Tsuno NH, Kojima M, Kuramitsu M, Tezuka K, Ikebe E, Ishizaka Y, Kenji M, Hangaishi A, Mikami A, Sugiura W, Ohmagari N, Mitsuya H.
   Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial.
   J Infect Chemother 29(9):869-874, 2023.
6. Terada M, Kinoshita-Iwamoto N, Saito S, Kutsuna S, Hangaishi A, Morioka S, Takahashi K, Miyata S, Ohmagari N.
   The safety of plasma apheresis from donors recovering from COVID-19 infection in Japan.
   Kamo-Imai A, Togano T, Sato M, Kawakami Y, Inaba K, Shimazu H, Igarashi S, Tanaka K,
   Transfus Apher Sci 62(3), 2023.
7. Inada M, Togano T, Terada M, Shiratori K, Tsuzuki S, Takamatsu Y, Saito S, Hangaishi A, Morioka S, Kutsuna S, Maeda K, Mitsuya H, Ohmagari N.
   Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma.
   Transfus Apher Sci 62(3), 2023.
8. Suzuki K, Mizuno S, Shimazu Y, Fuchida SI, Hagiwara S, Itagaki M, Nishiwaki K, Hangaishi A, Karasuno T, Kikuchi T, Shimizu M, Nishikawa A, Kobayashi T, Sunami K, Hiramoto N, Uchiyama H, Maruyama Y, Kanda Y, Ichinohe T, Atsuta Y, Yano S, Kawamura K; Working Group of the Japan Society; for Transplantation and Cellular Therapy.
   Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis.
   Eur J Haematol 110(4):444-454, 2023.
9. Nakaya Y, Koh H, Konuma T, Shimomura Y, Ishiyama K, Itonaga H, Hino M, Doki N, Nishida T, Ohigashi H, Matsuoka KI, Kanda Y, Maruyama Y, Sawa M, Eto T, Hiramoto N, Fukuda T, Atsuta Y, Nakamae H.
   HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA- Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome.
   Transplant Cell Ther 30(3):316.e1-316.e12, 2024.
10. Konuma T, Yamasaki S, Ishiyama K, Mizuno S, Hayashi H, Uchida N, Shimabukuro M, Tanaka M, Kuriyama T, Onizuka M, Ishiwata K, Sawa M, Tanaka T, Ohigashi H, Fujiwara SI, Matsuoka KI, Ota S, Nishida T, Kanda Y, Fukuda T, Atsuta Y, Nakasone H, Yanada M; Adult Acute Myeloid Leukemia and Donor/source Working Groups of the Japanese Society for Transplantation and Cellular Therapy.
    Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status. Transplant Cell Ther 30(2):215.e1-215.e18, 2024.
11. Nakagawa N, Ishiyama K, Usuki K, Takada S, Tomikawa T, Handa H, Katsuoka Y, Hirano D, Sezaki N, Sumi M, Fujisawa S, Taniguchi Y, Mugitani A, Yoshimura T, Ohtsuka E, Takase K, Suehiro Y, Ota S, Kajiguchi T, Maeda T, Yamamoto M, Ohtake S, Katsumi A, Kiyoi H, Matsumura I, Miyazaki Y.
    Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT.
    Ann Hematol 103(1):307-320, 2024.
12. Shimomura Y, Komukai S, Kitamura T, Tachibana T, Kurosawa S, Itonaga H, Tsukamoto S, Doki N, Katayama Y, Ito A, Sawa M, Ueda Y, Nakamae H, Nawa Y, Tanaka M, Arai Y, Ota S, Kataoka K, Nishida T, Kanda J, Fukuda T, Atsuta Y, Ishiyama K.
    The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation.
    Br J Haematol 204(2):612-622, 2024.
13. Ishiyama K, Yonemura Y, Kawaguchi T, Hosokawa K, Sugimori C, Ueda Y, Takamori H, Obara N, Noji H, Shirasugi Y, Ando K, Shichishima T, Ninomiya H, Chiba S, Nishimura JI, Kanakura Y, Nakao S.
    A longitudinal analysis of paroxysmal nocturnal haemoglobinuria-type cells in patients with bone marrow failure: Results of a prospective multicentre study in Japan.
    Br J Haematol 203(3):468-476, 2023.

口頭・ポスター発表－国際学会・研究会

1. Fujioka M, Itonaga H, Miyazaki Y, Shimomura Y, Uchida N, Takahashi S, Onizuka M, Ueda Y, Uehara Y, Tanaka M, Matsuhashi Y, Miyakoshi S, Tanaka H, Kawakita T, Ishimaru F, Kanda J, Ichinohe T, Atsuta Y, Ishiyama K.
   Impact of Conditioning Intensity and Regimen on Outcomes after Unrelated Cord Blood Transplantation for Patients with Myelodysplastic Syndrome.
   The 66th American Society of Hematology Annual Meeting and Exposition. San Diego, USA, Dec 2023.
2. Itonaga H, Miyazaki Y, FujiokaM, Ishiyama K, Aoki J, Doki N, Nishida T, Fukuda T, Uchida N, Ueda Y, Uehara Y, Katayama Y, Onizuka M, Ichinohe T, Atsuta Y.
   Prognostic Impact of Conditioning Intensity on Outcomes after Allogeneic Transplantation for MDS with Low Blasts.
   The 66th American Society of Hematology Annual Meeting and Exposition. San Diego, USA, Dec 2023.
3. Kurosawa S, Shimomura Y, Ishiyama K, Fuse K, Shimazu Y, Doki N, Uchida N, Tanaka M, Takahashi S, Sakurai M, Kobayashi H, Katayama Y, Takada S, Ozeki K, Nakamae H, Ishimaru F, Kanda Y, Ichinohe T, Atsuta Y, Itonaga H.
   Efficacy of Cord Blood Transplantation for the Management of Chronic Myelomonocytic Leukemia: A Registry-Based Study in Japan.
   The 66th American Society of Hematology Annual Meeting and Exposition. San Diego, USA, Dec 2023.
4. Zaimoku Y, Yamazaki H, Kanaya M, Hiramoto N, Ishiyama K, Uchida N, Doki N, Yamamoto R, Nishida T, Onodera K, Machida S, Kanda Y, Eto T, Ishimaru F, Onizuka M, Ichinohe T, Atsuta Y, Onishi Y.
   HLA Class I Genotypes Predict the Survival after Hematopoietic Stem Cell Transplantation in Immune Aplastic Anemia.
   The 66th American Society of Hematology Annual Meeting and Exposition. San Diego, USA, Dec 2023.
5. Konishi T, Matsuda K, Itonaga H, Doki N, Nishida T, Matsuoka K, Ikeda T, Kanda Y, Fukuda T, Kanda J, Nakamae H, Ichinohe T, Atsuta Y, Ishiyama K.
   Effect of Early Cytomegalovirus Reactivation on Relapse in Adult Patients with Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: A Registry Study from the Japan Society for Transplantation and Cellular Therapy (JSTCT)
   The 66th American Society of Hematology Annual Meeting and Exposition. San Diego, USA, Dec 2023.

口頭・ポスター発表－国内学会・研究会

1. 島津 浩, 那須 涼, 赤川 由里, 栂野 富輝, 石山 謙, 半下石 明.
   当院における中高齢者の骨髄系腫瘍に対する同種造血幹細胞移植の成績について.
   第85回日本血液学会学術集会. 東京, 10月, 2023.
2. 栂野 富輝, 上村 夕香理, 浅井 雄介, 早川 佳代子, 松永 展明, 寺田 麻里, 大津 洋, 鈴木 節子, 原 久男, 石金 正裕, 岩元 典子, 大曲 貴夫, 半下石 明
   入院前の抗血小板療法、抗凝固療法がCOVID-19入院患者の重症度に与える影響
   第85回日本血液学会学術集会. 東京, 10月, 2023.
3. 岡田 陽介, 木村 文彦, 栗田 尚樹, 高橋 寛行, 島津 裕, 水野 昌平, 内田 直之, 片岡 圭亮,平本 展大, 太田 秀一, 賀古 真一, 塚田 信弘, 神田 善伸, 倉橋 信悟, 土岐 典子, 西川 彰則, 金 成元, 半下石 明, 諫田 淳也, 福田 隆浩, 熱田 由子, 近藤 英生, 河村 浩二, 仲宗根 秀樹
   アグレッシブ非ホジキンリンパ腫および多発性骨髄腫に対する自家移植後に起こる血小板生着遅延の影響
   第85回日本血液学会学術集会. 東京, 10月, 2023.
4. 島津 浩, 那須 涼, 栂野 富輝, 千葉 みゆき, 石山 謙, 半下石 明
   当院における高齢者の骨髄系腫瘍に対する臍帯血移植症例の成績について
   第46回日本造血・免疫細胞療法学会総会, 東京,3月,2024．
5. 島津 浩, 那須 涼, 栂野 富輝, 塩川 夏海, 田部 葵, 千葉 みゆき, 小山内 泰代, 石山 謙, 半下石 明
   当院における外国人の同種移植2例から学んだチーム医療としての関わりの重要性
   第46回日本造血・免疫細胞療法学会総会, 東京,3月,2024.
6. 小澤 征紀, 那須 涼, 青木 淳, 島津 浩, 栂野 富輝, 石山 謙, 半下石 明
   チロシンキナーゼ阻害剤不耐容の慢性骨髄性白血病に対してアシミニブが有効であった2例
   第20回 日本血液学会関東甲信越地方会．東京,3月,2024．
7. 平川 良, 塚田 晃成, 栂野 富輝, 高崎 仁, 波多野 裕斗, 杉野 美緒, 仲村 実花子, 植木 裕太郎, 岩﨑 美香, 森田 智枝, 波多野 聡, 石田 あかね, 橋本 理生, 鈴木 学, 仲 剛, 草場 勇作, 軒原 浩, 泉 信有, 半下石 明, 放生 雅章
   播種性症を契機とし、の混合感染を生じた有毛細胞白血病の一例
   第184回日本結核・非結核性抗酸菌症学会関東支部学会, 東京, 9月,2023

著書・総説

単行本－和文

1. 半下石　明.
   貧血．
   本日の内科外来　改訂第2版、村川裕二　編集、南江堂、東京、p31-35、2023.

総説－和文

1. 半下石　明　
   One Point Advice「新型コロナウイルスワクチン接種後の血小板減少」.　
   特集　抗菌薬の使い方.
   Medical Practice 40（4）、文光堂、東京、p642、2023.